Navigation Links
Labopharm Reports Results for Third Quarter Fiscal 2007
Date:11/9/2007

he treatment of depression," said Mr. Howard-Tripp. "Trazodone has a proven history of efficacy and we believe that by controlling the blood concentration levels through our Contramid(R) controlled-release technology, we can offer a once-daily formulation with a potentially improved side effect profile that takes advantage of trazodone's unique sedative effects, eliminating the need for adjunctive therapy often associated with other anti-depressants to address related conditions such as poor sleep quality. We look forward to reporting data from our Phase III study in the second quarter of next year."

Other Development Programs

Labopharm continues to advance the development programs for other product candidates in its pipeline, including its programs to develop a twice-daily tramadol-acetaminophen combination formulation and a twice-daily acetaminophen formulation, both of which are based on the Company's proprietary Contramid(R) technology. The Company is currently in the process of preparing for pivotal studies for the tramadol-acetaminophen formulation, which it expects to begin imminently.

Financial Results

Revenue for the third quarter of fiscal 2007 increased to $5.1 million from $3.3 million for the third quarter of fiscal 2006. Product sales increased to $2.8 million from $1.1 million with the increase being the result of higher volumes due to shipments of once-daily tramadol to a larger number of markets in the third quarter of fiscal 2007 compared to the third quarter of fiscal 2006, as well as higher average selling prices in the third quarter of fiscal 2007, primarily as a result of launch of the product in Canada, where selling prices are higher than in Europe. Product sales for the third quarter of fiscal 2007 consisted of follow-on shipments of once-daily tramadol to our marketing partners in Europe for distribution in various markets, as well as initial shipments to Paladin Labs Inc. for distribution in Canada.

Gross marg
'/>"/>

SOURCE Labopharm Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
8. Haemacure Reports Third Quarter 2007 Results
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... recently FDA-approved device has been shown to reduce seizures ... 50 percent. When coupled with an innovative electrode placement ... facilitated the complete elimination of seizures in nearly half ... clinical trials. , That,s good news for a large ... living with epilepsy whose seizures can,t be controlled with ...
(Date:4/22/2014)... Approximately 15 percent of all lung cancers are ... and often develop resistance to chemotherapy. However, researchers ... revealed new insights into the mechanisms leading to ... , Chemotherapies work primarily by mediating B-cell ... for regulating cell death. Depending on their function, ...
(Date:4/22/2014)... Working with mice and rabbits, Johns Hopkins scientists have ... and breakdown, successfully preventing the development of atherosclerosis, the ... number-one cause of death among humans. The condition develops ... renders them stiff, narrowed and hardened, greatly reducing their ... and the brain. , In a series of experiments, ...
(Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
(Date:4/22/2014)... Lab researchers have demonstrated the first size-based form ... the membranes of living cells. This unique physical ... information critical to whether a cell lives or ... be obtained through conventional microscopy. , "We,ve developed ... means to both probe and manipulate membrane assemblies, ...
Breaking Medicine News(10 mins):Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3
... FRIDAY, June 25 (HealthDay News) -- When it comes to ... you see, hear, and maybe even smell influence your assessment. ... the chair you,re sitting on, the mug of coffee you,re ... behavior. In a series of experiments, researchers at ...
... The American Physical Society, a leading organization of ... future energy technologies that will strengthen energy security and ... fuel exploration as evidenced by the BP oil spill. ... in the history of the nation has caused ...
... , FRIDAY, June 25 (HealthDay News) -- It,s a ... prescription vial containing years-old medication or an over-the-counter cold ... unless they,re spring-cleaning, many people don,t bother throwing away ... to the toilet and flush the products away. ...
... of America (GSA) the nation,s largest interdisciplinary organization ... Helene Fung, PhD, of the Chinese University of Hong ... and Paul B. Baltes Foundation Award in Behavioral and ... outstanding early career contributions in behavioral and social gerontology. ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, ... risk of dying from a heart attack, stroke or other ... diabetes in one of every 10 deaths from cardiovascular disease, ... "We have known for decades that people with diabetes are ...
... ... world to its new line of American made e-juice. , ... (PRWEB) June 25, 2010 -- Leading electronic ... comfort for not only its loyal customers, but all electronic cigarette users known as "Vapers" ...
Cached Medicine News:Health News:What You Touch May Make You a 'Softie' or Play 'Hard Ball' 2Health News:What You Touch May Make You a 'Softie' or Play 'Hard Ball' 3Health News:APS urges greater federal investment in energy research 2Health News:Outdated Meds Pose Problems If Kept or Tossed 2Health News:Outdated Meds Pose Problems If Kept or Tossed 3Health News:Fung to receive GSA's 2010 Baltes Foundation Award 2Health News:Diabetes May Double Risk of Heart Attack, Stroke 2Health News:Diabetes May Double Risk of Heart Attack, Stroke 3Health News:Leading Electronic Cigarette Manufacturer Vapure Announces U.S. Made E-Liquid 2
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
(Date:1/14/2014)... HILLS, Calif. , Jan. 14, 2014 The Brandeis Medical ... Los Angeles a premier and affordable laser tattoo removal ... special. Dr. Brandeis, focus is in providing high quality cosmetic services ... all patients. " Southern California has ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... SOUTHAMPTON, England, March 24 , ... Completes Phase I Dosing , ... medical needs, announces further clinical trial progress with its ... hypertrophy (BPH) and VA111913 for dysmenorrhoea. The Phase IIa,trial ...
... today announced positive results from a Phase 1 trial ... in vitro anti-pseudomonal activity. The results from ... well tolerated, with a clinical and laboratory safety profile ... toxicity was observed, even at the highest dose regimen ...
Cached Medicine Technology:Vantia Therapeutics' Pipeline Continues to Mature 2Vantia Therapeutics' Pipeline Continues to Mature 3Vantia Therapeutics' Pipeline Continues to Mature 4Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity 2
Fine pointed grooved jaws with smooth curve from tip to finger grip style handle. Dull finish....
This forcep was designed to eliminate the occasional tearing of tissue which may occur when grasping the lips of an incision with a traditional. 12 forceps. The rows of blunt teeth are gentle yet pro...
Straight shafts with 1 x 2 teeth. Flat handle with polished finish....
Straight shafts with 90 degrees, 2 x 3 teeth and tying platform. Serrated handle with polished finish. Most popular size or model....
Medicine Products: